Prostate Cancer Update: 2007
August 2008
in “
Current Opinion in Internal Medicine
”
TLDR In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
In 2007, prostate cancer research made strides in risk assessment, diagnosis, and treatment. Key findings included the prognostic value of the tertiary Gleason 5 pattern and PSA levels post-finasteride treatment, the benefits of active treatment in elderly men, and the development of a comprehensive nomogram for salvage radiotherapy. Studies highlighted the cardiovascular risks associated with androgen deprivation therapy (ADT), with one study of 4892 patients showing increased cardiovascular death associated with ADT, and another indicating ADT could hasten fatal myocardial infarction in men over 65. A multinational trial of 809 men found that atrasentan did not improve outcomes in hormone-refractory prostate cancer (HRPC), and a phase II study of 82 patients provided baseline data for taxane-resistant HRPC. The research underscored the need for personalized treatments and further investigation into ADT's cardiovascular effects and treatments for HRPC.
